http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-102014022024-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1f861d7dfdde7b233339d4838364a8e8 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-355 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 |
| filingDate | 2014-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc87e96f7c57f0910059008c4e92da91 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee45d82768869a48ec53b44356368c4d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24808399a088fe3621c48e201a06c33c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a12366bfa8c6884b5b201efc3b49e369 |
| publicationDate | 2016-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-102014022024-A2 |
| titleOfInvention | antitumor pharmaceutical compositions containing solid lipid nanoparticles co-encapsulated with an anthracycline class compound and a vitamin E derivative with antitumor activity and use |
| abstract | antitumor pharmaceutical compositions containing solid lipid nanoparticles co-encapsulated with an anthracycline class compound and a vitamin E derivative with antitumor activity and use. The present technology consists of pharmaceutical compositions containing solid lipid nanoparticles (nls) co-encapsulating an anthracycline class compound, preferably doxorubicin, and an anti-tumor vitamin E derivative, preferably tocopheryl α-succinate, bonded in the form of ionic pair, whether or not tgps (d-alpha tocopheryl polyethylene glycol 1000 succinate) as surfactant and / or donor of tocopheryl succinate for the treatment of solid tumors. The nanoparticles have characteristics suitable for intravenous administration and high cytotoxicity against the tumor lines, besides promoting a controlled release of the anthracycline class compound, preferably doxorubicin. |
| priorityDate | 2014-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 96.